Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin

Arch Dermatol. 2007 Aug;143(8):1046-50. doi: 10.1001/archderm.143.8.1046.


Background: Schnitzler syndrome is characterized by chronic urticarial rash and monoclonal IgM gammopathy and is sometimes associated with periodic fever, arthralgias, and bone pain. Current treatment is unsatisfactory.

Observations: Eleven patients with Schnitzler syndrome were treated with oral pefloxacin mesylate (800 mg/d). In 10 patients, we observed a dramatic and sustained improvement of urticarial and systemic manifestations. Corticosteroid therapy could be stopped or reduced in 6 patients. In 9 patients, pefloxacin was administered for more than 6 months (<or= 10 years), with a good safety profile.

Conclusions: Pefloxacin therapy can be considered for patients with Schnitzler syndrome because it usually improves chronic urticaria and the systemic symptoms of the disease.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / therapeutic use*
  • Cohort Studies
  • Drug Therapy, Combination
  • Glucocorticoids / administration & dosage
  • Humans
  • Middle Aged
  • Pefloxacin / administration & dosage
  • Pefloxacin / therapeutic use*
  • Retrospective Studies
  • Schnitzler Syndrome / drug therapy*
  • Treatment Outcome


  • Anti-Infective Agents
  • Glucocorticoids
  • Pefloxacin